SinoMab BioScience Voluntarily Withdraws BLA for Suciraslimab in China Citing Need for Additional Data
CompanyDrug

SinoMab BioScience Voluntarily Withdraws BLA for Suciraslimab in China Citing Need for Additional Data

Mabwell Signs Licensing Agreement with Unilab for Denosumab Biosimilars in the Philippines
CompanyDeals

Mabwell Signs Licensing Agreement with Unilab for Denosumab Biosimilars in the Philippines

Innovent Biologics and JD Health Form Strategic Partnership to Enhance Drug Supply and Healthcare Services
CompanyDeals

Innovent Biologics and JD Health Form Strategic Partnership to Enhance Drug Supply and Healthcare Services

Shanghai Henlius Biotech Initiates US Patient Dosing in Phase III Trial for HER2-Positive Gastric Cancer
CompanyDrug

Shanghai Henlius Biotech Initiates US Patient Dosing in Phase III Trial for HER2-Positive Gastric Cancer

Bayer AG's Kerendia Approved by FDA to Treat Adult Heart Failure with Ejection Fraction ≥40%
CompanyDrug

Bayer AG’s Kerendia Approved by FDA to Treat Adult Heart Failure with Ejection Fraction ≥40%

Sichuan Biokin's Iza-bren Approved for Phase II Clinical Study in Renal Cell Carcinoma
CompanyDrug

Sichuan Biokin’s Iza-bren Approved for Phase II Clinical Study in Renal Cell Carcinoma

Hunan Mabgeek Biotech Files for Hong Kong IPO to Expand Innovative Biologics Pipeline
CompanyDeals

Hunan Mabgeek Biotech Files for Hong Kong IPO to Expand Innovative Biologics Pipeline

GSK's Arexvy RSV Vaccine Expansion for Adults 18-49 Receives FDA Review
CompanyDrug

GSK’s Arexvy RSV Vaccine Expansion for Adults 18-49 Receives FDA Review

Dizal's Sunvozertinib Included in NCCN Guidelines for EGFR Exon20ins NSCLC Treatment
Others

Dizal’s Sunvozertinib Included in NCCN Guidelines for EGFR Exon20ins NSCLC Treatment

Boao Super Hospital Introduces Xiaflex for Non-Surgical Peyronie's Disease Treatment
CompanyDrug

Boao Super Hospital Introduces Xiaflex for Non-Surgical Peyronie’s Disease Treatment

CompanyDeals

Lexenpharm Partners with AptarGroup for Single-Dose Nasal Spray Services in Greater China

Eolas Therapeutics Gains Full Rights to AZD4041 for Opioid Use Disorder Development
CompanyDeals

Eolas Therapeutics Gains Full Rights to AZD4041 for Opioid Use Disorder Development